title: Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine.
abstract: Ranolazine is clinically approved for treatment of angina pectoris and is a potential candidate for antiarrhythmic, antiepileptic, and analgesic applications. These therapeutic effects of ranolazine hinge on its ability to inhibit persistent or late Na(+) currents in a variety of voltage-gated sodium channels. Extracellular acidosis, typical of ischemic events, may alter the efficiency of drug/channel interactions. In this study, we examined pH modulation of ranolazine's interaction with the cardiac sodium channel, Nav1.5. We performed whole-cell path clamp experiments at extracellular pH 7.4 and 6.0 on Nav1.5 transiently expressed in HEK293 cell line. Consistent with previous studies, we found that ranolazine induced a stable conformational state in the cardiac sodium channel with onset/recovery kinetics and voltage-dependence resembling intrinsic slow inactivation. This interaction diminished the availability of the channels in a voltage- and use-dependent manner. Low extracellular pH impaired inactivation states leading to an increase in late Na(+) currents. Ranolazine interaction with the channel was also slowed 4-5 fold. However, ranolazine restored the voltage-dependent steady-state availability profile, thereby reducing window/persistent currents at pH 6.0 in a manner comparable to pH 7.4. These results suggest that ranolazine is effective at therapeutically relevant concentrations (10 μM), in acidic extracellular pH, where it compensates for impaired native slow inactivation.
authors.affiliation: Molecular Cardiac Physiology Group, Department of Biomedical Physiology and Kinesiology, Simon Fraser University Burnaby, BC, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Sokolov
authors.forename: C H
authors.initials: CH
authors.lastname: Peters
authors.forename: S
authors.initials: S
authors.lastname: Rajamani
authors.forename: P C
authors.initials: PC
authors.lastname: Ruben
keywords: Nav1.5; acidosis; cardiac sodium channel; electrophysiology; ranolazine